JNJ 1493
Alternative Names: JNJ-1493Latest Information Update: 15 Feb 2024
At a glance
- Originator Xencor
- Developer Johnson & Johnson Innovative Medicine; Xencor
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I B-cell lymphoma
Most Recent Events
- 15 Feb 2024 Phase-I clinical trials in B-cell lymphoma (Parenteral), before February 2024 (Johnson & Johnson pipeline, February 2024)
- 21 Dec 2023 Preclinical trials in B-cell lymphoma in USA (Parenteral) (Xencor pipeline; December 2023)